CL2018000349A1 - 5-Bromo-2,6-di- (1h-pyrazol-1-yl) pyrimidin-4-amine for use in the treatment of canker. - Google Patents

5-Bromo-2,6-di- (1h-pyrazol-1-yl) pyrimidin-4-amine for use in the treatment of canker.

Info

Publication number
CL2018000349A1
CL2018000349A1 CL2018000349A CL2018000349A CL2018000349A1 CL 2018000349 A1 CL2018000349 A1 CL 2018000349A1 CL 2018000349 A CL2018000349 A CL 2018000349A CL 2018000349 A CL2018000349 A CL 2018000349A CL 2018000349 A1 CL2018000349 A1 CL 2018000349A1
Authority
CL
Chile
Prior art keywords
treatment
bromo
canker
pyrazol
pyrimidin
Prior art date
Application number
CL2018000349A
Other languages
Spanish (es)
Inventor
Alberto Camacho Gomez Juan
Scott Cameron John
Bilic Sanela
Cesar Castro-Palomino Laria Julio
Roland Howard Danny Jr
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Publication of CL2018000349A1 publication Critical patent/CL2018000349A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A 5-BROMO-2,6-DI- (1H-PIRAZOL-1-II) PIRIMIDIN-4-AMINA, SUS SALES FARMACÉUTICAMENTE ACEPTABLES Y SUS CO-CRISTALES Y A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS PARA USO EN EL TRATAMIENTO DEL CÁNCER, PARTICULARMENTE CARCINOMAS, ESPECÍFICAMENTE PARA USO EN EL TRATAMIENTO DEL CÁNCER DE PULMÓN, Y MÁS ESPECÍFICAMENTE PARA SU USO EN EL TRATAMIENTO DEL CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS.THE PRESENT INVENTION REFERS TO 5-BROMO-2,6-DI- (1H-PIRAZOL-1-II) PIRIMIDIN-4-AMINA, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND ITS CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS FOR USE IN THE TREATMENT OF CANCER, PARTICULARLY CARCINOMAS, SPECIFICALLY FOR USE IN THE TREATMENT OF LUNG CANCER, AND MORE SPECIFICALLY FOR USE IN THE TREATMENT OF LUNG CANCER OF NON-SMALL CELLS.

CL2018000349A 2015-08-11 2018-02-07 5-Bromo-2,6-di- (1h-pyrazol-1-yl) pyrimidin-4-amine for use in the treatment of canker. CL2018000349A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382425 2015-08-11
US201662335984P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
CL2018000349A1 true CL2018000349A1 (en) 2018-09-07

Family

ID=65563017

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000349A CL2018000349A1 (en) 2015-08-11 2018-02-07 5-Bromo-2,6-di- (1h-pyrazol-1-yl) pyrimidin-4-amine for use in the treatment of canker.

Country Status (13)

Country Link
JP (1) JP6964113B2 (en)
KR (1) KR102226100B1 (en)
CL (1) CL2018000349A1 (en)
DK (1) DK3334431T3 (en)
ES (1) ES2761910T3 (en)
HK (1) HK1249409B (en)
HR (1) HRP20192192T1 (en)
HU (1) HUE046646T2 (en)
IL (1) IL257350A (en)
LT (1) LT3334431T (en)
PT (1) PT3334431T (en)
RU (1) RU2745560C2 (en)
ZA (1) ZA201800792B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365960B1 (en) * 2010-03-31 2012-06-04 Palobiofarma, S.L NEW ANTAGONISTS OF ADENOSINE RECEPTORS.

Also Published As

Publication number Publication date
RU2745560C2 (en) 2021-03-29
KR102226100B1 (en) 2021-03-10
PT3334431T (en) 2020-01-06
ES2761910T3 (en) 2020-05-21
JP6964113B2 (en) 2021-11-10
DK3334431T3 (en) 2020-01-02
ZA201800792B (en) 2019-06-26
HRP20192192T1 (en) 2020-03-06
IL257350A (en) 2018-03-29
LT3334431T (en) 2019-12-27
HK1249409B (en) 2020-05-08
KR20200057790A (en) 2020-05-26
HUE046646T2 (en) 2020-03-30
JP2019218346A (en) 2019-12-26
RU2018108050A (en) 2019-09-13
RU2018108050A3 (en) 2020-02-17

Similar Documents

Publication Publication Date Title
CY1122966T1 (en) 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE THERAPEUTIC TREATMENT OF CANCER
SV2018005687A (en) DIHYDROIMIDAZOPIRAZINONA DERIVATIVES USED IN CANCER TREATMENT
NI201600144A (en) QUINOXALINE DERIVATIVES USEFUL AS MODULATORS OF FGFR KINASE
CL2016002148A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutically acceptable pharmaceutical compositions and compositions prepared therefrom.
UY35590A (en) NEW COMPOUNDS FOR CANCER TREATMENT
CL2015002194A1 (en) Erk inhibitors and their uses
CL2014001793A1 (en) Compounds derived from substituted 1,3,5-triazines and their salts, as inhibitors of mutant idh2; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CR20170116A (en) COMPOUNDS THAT INHIBIT THE PROTEIN MCL-1
NI201800042A (en) NEW DERIVATIVES OF PIRROLO [2,3-D] PYRIMIDINE AS DUAL INHIBITORS OF DYRK1 / CLK1
EA202091115A1 (en) QUINAZOLINE DERIVATIVES USED FOR HIV TREATMENT
EA201791305A1 (en) CONDENSED PYRIMIDINES FOR TREATING HIV
MA39986A (en) Purine derivatives as cd73 inhibitors for the treatment of cancer
CL2016001973A1 (en) Nucleoside derivatives substituted with 4'-difluoromethyl as inhibitors of influenza arn replication.
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CL2013002517A1 (en) Compounds derived from 5-fluoro-2'-deoxyuridine phosphoramidate; preparation procedure; pharmaceutical composition that includes them; its use in the treatment or prophylaxis of cancer.
CL2015002608A1 (en) Amino-pyrazole compound and related medicinal uses.
CL2016003214A1 (en) Indolizine derivatives as phosphoinositide-3 kinase inhibitors
NI201500096A (en) CHEMICAL COMPOUNDS
CL2016002091A1 (en) Triazine compound and its use for medicinal purposes
CL2017003107A1 (en) 2- (Pyrazolopyridin-3-yl) pyrimidine derivatives as jak inhibitors
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
CL2019001993A1 (en) Selective inhibitors of jak1.
CL2017000682A1 (en) Novel imidazopyridazine compounds and their use.
UY36003A (en) AMIDA DERIVATIVES, PREPARATION PROCESSES AND COMPOSITIONS, USEFUL IN AFFECTIONS ASSOCIATED WITH THE SUB-TYPE 1 RECEIVER OF OREXINA.
CL2015003195A1 (en) Purine derivatives as cb2 receptor agonists.